Nu-Med Plus (NUMD) Free Cash Flow Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Free Cash Flow Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 129.12 Bn | 125.64 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 119.32 Bn | 110.10 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 73.63 Bn | 73.09 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 52.14 Bn | 47.89 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.48 Bn | 32.54 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 34.06 Bn | 31.95 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | -14.34% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,001.56% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -66.14% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 84.68% |
| Dec 31, 2021 | 71.70% |
| Sep 30, 2021 | 59.42% |
| Jun 30, 2021 | 54.91% |
| Mar 31, 2021 | 16.75% |
| Dec 31, 2020 | 42.85% |
| Sep 30, 2020 | -33.87% |
| Jun 30, 2020 | -22.25% |
| Mar 31, 2020 | 61.41% |